Telix Pharmaceuticals (NASDAQ:TLX) Sets New 1-Year Low – What’s Next?

Telix Pharmaceuticals Limited (NASDAQ:TLX) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $7.12 and last traded at $7.13, with a volume of 55741 shares. The stock had previously closed at $7.43.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 23rd. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Finally, Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Down 2.4%

The company’s fifty day moving average is $8.13 and its 200 day moving average is $9.83.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter worth about $3,037,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals during the second quarter valued at approximately $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $297,000. Millennium Management LLC purchased a new stake in Telix Pharmaceuticals in the 3rd quarter worth approximately $1,883,000. Finally, Lazard Asset Management LLC bought a new position in Telix Pharmaceuticals in the 3rd quarter valued at $1,097,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.